# BioMarin Pharmaceutical (BMRN) — Financial Analysis

**Exchange:**   
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-10  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/BMRN/thesis · /stocks/BMRN/memo

## Financial Snapshot

---
title: "Step 04 — Financial Snapshot & Quality"
ticker: BMRN
company: BioMarin Pharmaceutical Inc.
source: coverage-next-full
date: 2026-06-10
step: "04"
---

### Step 04 — Financial Snapshot & Quality: BioMarin Pharmaceutical (BMRN)

#### 1. Statement Quality Adjustments

##### Revenue Quality: HIGH
BioMarin's revenue recognition is straightforward — product sales recognized at point-of-sale (specialty pharmacy / hospital delivery) with standard gross-to-net deductions (chargebacks, rebates, returns) [S1]. No complex milestone recognition, no subscription/SaaS dynamics. Revenue quality is high.

Key adjustments:
- **Gross-to-net deductions:** ~6–8% of gross sales; standard for rare disease; improving as government rebate exposure is manageable
- **No off-balance-sheet revenues:** All revenue flows through consolidated P&L

##### Earnings Quality: MEDIUM (GAAP distorted; Non-GAAP representative)

GAAP earnings are **materially distorted** by two non-cash items that require adjustment for economic analysis:

| Item | FY2024 | FY2023 | FY2022 | Explanation |
|------|--------|--------|--------|-------------|
| Intangibles amortization | ~$610M | ~$650M | ~$680M | From historical acquisitions (Naglazyme, Vimizim programs acquired at significant premium) |
| Stock-based compensation (SBC) | ~$207M | ~$195M | ~$181M | 7–8% of revenue; high but within biopharma range |
| Total non-cash adjustments | ~$817M | ~$845M | ~$861M | |

After these adjustments, non-GAAP operating income in FY2024 was ~$815M (28.6% margin) vs. GAAP operating income of ~$436M (15.3%) [S1].

**Assessment:** The intangibles amortization is real economic value erosion (from prior capital deployed), but it is non-recurring in nature (declining each year as intangibles are amortized off). The 2020 "net income" of $854M was entirely the result of a $903M deferred tax benefit — economic operating performance was still loss-generating. Investors should use FCF and Non-GAAP operating income as primary metrics [S2].

##### Balance Sheet Quality: HIGH
- Net cash position as of FY2024: ~$347M
- Convertible notes reduced from $1.08B to $595M during FY2024 (significant capital return signal)
- No goodwill impairment concerns on MPS products (continued strong cash generation)
- Roctavian-related write-offs largely absorbed in FY2023–FY2024

---

#### 2. Three-Statement Financials (FY2020–FY2024)

##### Income Statement Summary

| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|--------|--------|--------|--------|--------|--------|
| Revenue ($M) | 1,840 | 2,004 | 2,251 | 2,546 | 2,849 |
| Gross Profit ($M) | 1,380 | 1,524 | 1,711 | 1,986 | 2,271 |
| Gross Margin | 75.0% | 76.0% | 76.0% | 78.0% | 79.7% |
| R&D ($M) | ~740 | ~760 | ~832 | ~765 | ~712 |
| SG&A ($M) | ~380 | ~390 | ~496 | ~458 | ~513 |
| GAAP Op. Income ($M) | (100) | (126) | 66 | 197 | 436 |
| GAAP Op. Margin | (5.4%) | (6.3%) | 2.9% | 7.7% | 15.3% |
| GAAP Net Income ($M) | 854* | (118) | (6) | 174 | ~429 |
| GAAP EPS | $4.48* | ($0.60) | ($0.03) | $0.87 | $2.21 |
| Non-GAAP EPS | est. ~$1.50 | est. ~$1.80 | est. ~$2.20 | est. ~$2.80 | $3.52 |

*FY2020 GAAP net income distorted by $903M non-cash deferred tax benefit [S2]

##### Cash Flow Summary

| Metric | FY2022 | FY2023 | FY2024 |
|--------|--------|--------|--------|
| Operating CF ($M) | ~113 | 160 | 573 |
| Capex ($M) | (~63) | (~97) | (~86) |
| Free Cash Flow ($M) | ~50 | 63 | 487 |
| SBC ($M) | ~181 | ~195 | ~207 |
| D&A ($M) | ~740 | ~715 | ~700 est. |

**FCF inflection in FY2024 (+672% YoY) is the defining financial event** — driven by operating leverage, lower R&D spend as Roctavian wound down, and improved working capital [S1].

##### Balance Sheet Summary (Year-End)

| Metric | FY2022 | FY2023 | FY2024 |
|--------|--------|--------|--------|
| Cash & Equivalents ($M) | ~628 | ~735 | ~942 |
| Total Assets ($M) | ~7,800 | ~7,900 | ~8,100 |
| LT Debt (Face) ($M) | ~1,100 | ~1,082 | ~595 |
| Net Cash/(Debt) ($M) | (~472) | (~347) | ~347 |
| Total Equity ($M) | ~5,200 | ~5,400 | ~5,660 |

---

#### 3. Adversarial Research Sweep

*Note: Transcripts not used. Sources are SEC filings, press releases, investor materials, and publicly available short reports.*

##### Finding A: Roctavian — Capital Destruction at Scale
**Allegation/Risk:** BioMarin destroyed over $1 billion in capital developing and launching a gene therapy (Roctavian/valoctocogene roxaparvovec) for hemophilia A that failed commercially, raising questions about capital allocation discipline and management judgment.

**Assessment:** SUBSTANTIATED AS HISTORICAL FACT.
- BioMarin paid ~$450M to acquire Spark Therapeutics' hemophilia A program (later terminated after Roche acquired Spark)
- Roctavian received FDA approval August 2023, priced at $2.9M — the highest drug price in history at that time
- The product failed commercially: payers refused to cover, Hemlibra competition was entrenched, and factor VIII durability was uncertain
- BioMarin announced wind-down in FY2024; total cash spent on Roctavian development exceeds $1B
- **Current relevance:** This failure precipitated the CEO change and the cost transformation program. New CEO Alexander Hardy was brought in specifically to course-correct. Risk to current thesis: NEW MANAGEMENT TEAM, same science organization — does the corporate culture that enabled this mistake persist? [S3]

##### Finding B: European Pricing Pressure as Chronic Headwind
**Allegation/Risk:** BioMarin's European ERT revenues are subject to annual HTA renegotiations that structurally compress pricing 1–5% per year, creating a math problem where volume growth is needed to offset price.

**Assessment:** SUBSTANTIATED — LOW CURRENT SEVERITY.
- Germany (AMNOG), UK (NICE), Italy (AIFA), and France (HAS) all renegotiate rare disease pricing
- NAGLAZYME and VIMIZIM have faced periodic pricing reductions
- Europe is ~35% of revenue; 3% annual price erosion on European ERT = ~$25M headwind
- Offset by geographic expansion (VOXZOGO) and modest volume growth
- Not an existential risk but a structural drag that limits upside from ERT products [S4]

##### Finding C: SBC as Percentage of Revenue — Worth Monitoring
**Allegation/Risk:** BioMarin's SBC ($207M in FY2024, 7.3% of revenue) dilutes shareholders and inflates non-GAAP metrics.

**Assessment:** PARTIALLY VALID — WITHIN BIOPHARMA NORMS.
- 7–8% SBC/Revenue is elevated vs. mature pharma but typical for mid-cap biopharma retaining scientific talent
- Shares outstanding have increased from ~175M (FY2019) to ~195M (FY2024) — modest dilution (~11% over 5 years)
- Not a disqualifying concern; should be monitored for acceleration [S1]

##### Finding D: Amicus Acquisition — Thesis Test
**Allegation/Risk:** BioMarin acquired Amicus Therapeutics in 2025 for reportedly $4B+, adding an ERT competitor (migalastat/AT-GAA) in Fabry disease and Pompe disease — areas where BioMarin does not have leading products.

**Assessment:** OPEN QUESTION — CAPITAL ALLOCATION RISK.
- Migalastat (Galafold) is approved for Fabry disease; AT-GAA (cipaglucosidase alfa + miglustat) is approved in some markets for Pompe disease
- These are adjacencies, not direct overlaps with existing BioMarin products
- Price paid vs. revenue generated will be graded in Step 07
- Risk: Another large capital commitment in a disease area where BioMarin lacks incumbent advantage; mirrors Roctavian pattern
- Bull case: Amicus revenue ($250–350M run rate) at reasonable multiple; commercial teams complement each other [S5]

---

#### 4. Financial Quality Summary

| Dimension | Score | Notes |
|-----------|-------|-------|
| Revenue quality | High | Straightforward product sales, gross-to-net well-understood |
| Earnings quality (GAAP) | Medium | Distorted by non-cash amortization; use Non-GAAP + FCF |
| Cash flow quality | High | FCF inflecting strongly; capital allocation improving |
| Balance sheet quality | High | Net cash, debt reduction underway |
| Acquisition track record | Low-Medium | Roctavian failure; Amicus TBD |
| Overall | **Medium-High** | Underlying economics strong; GAAP earnings misleading |

---

#### 5. Thesis Tracker Update

*Adversarial sweep confirms: Roctavian was the key bear-case data point (capital destruction), now largely historical. The real live risk is Amicus capital allocation (yet to be proven) and ongoing European pricing. No accounting fraud allegations, no revenue recognition concerns. Financial quality is sound when adjusted for non-cash items.*

---

#### 6. Source Index

| ID | Source | Date |
|----|--------|------|
| S1 | BMRN_financials/sec_filings/10K_FY2024_summary.md | 2026-06-10 |
| S2 | BMRN_financials/sec_filings/10K_FY2022_summary.md | 2026-06-10 |
| S3 | BMRN_financials/industry/competitive_landscape.md | 2026-06-10 |
| S4 | BMRN_financials/industry/market_overview.md | 2026-06-10 |
| S5 | BMRN_financials/other/consensus.md | 2026-06-10 |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/BMRN/fundamental

## Navigation

- Overview: /stocks/BMRN
- Financials (this page): /stocks/BMRN/financials
- Thesis: /stocks/BMRN/thesis
- Investment Memo: /stocks/BMRN/memo
- Coverage universe: /stocks